Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
QuantumLeap Healthcare Collaborative
Novartis
Kivu Bioscience Inc.
FindCure Biosciences (ZhongShan) Co., Ltd.
Hoffmann-La Roche
Aveni Foundation
Bayer
University of California, Irvine
Eastern Cooperative Oncology Group
ViroMissile, Inc.
Dana-Farber Cancer Institute
Kaiser Permanente
Washington University School of Medicine
University of Florida
Essen Biotech
Angiex, Inc.
MacroGenics
Avacta Life Sciences Ltd
Alliance for Clinical Trials in Oncology
University of Nebraska
Adela, Inc
M.D. Anderson Cancer Center
University of Southern California
Eli Lilly and Company
Var2 Pharmaceuticals
National Institutes of Health Clinical Center (CC)
University of Illinois at Chicago
Mayo Clinic
Tanabe Pharma America, Inc.
Stella Pharma Corporation
Bayer
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Young Adult Survivors United
AVM Biotechnology Inc
Pfizer
British Columbia Cancer Agency
Washington University School of Medicine
Travera Inc
Washington University School of Medicine
Eli Lilly and Company
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
Washington University School of Medicine
Institut Bergonié
Eli Lilly and Company
University of California, Irvine